Wells Fargo & Company Neurocrine Biosciences Inc Transaction History
Wells Fargo & Company
- $407 Billion
- Q2 2024
A detailed history of Wells Fargo & Company transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Wells Fargo & Company holds 234,969 shares of NBIX stock, worth $28.3 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
234,969
Previous 221,814
5.93%
Holding current value
$28.3 Million
Previous $30.6 Million
5.74%
% of portfolio
0.01%
Previous 0.01%
Shares
18 transactions
Others Institutions Holding NBIX
# of Institutions
623Shares Held
95.4MCall Options Held
661KPut Options Held
221K-
Black Rock Inc. New York, NY14.2MShares$1.71 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.1MShares$1.21 Billion0.03% of portfolio
-
State Street Corp Boston, MA4.61MShares$555 Million0.03% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny2.47MShares$297 Million0.6% of portfolio
-
Jpmorgan Chase & CO New York, NY2.36MShares$285 Million0.03% of portfolio
About NEUROCRINE BIOSCIENCES INC
- Ticker NBIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 95,639,296
- Market Cap $11.5B
- Description
- Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...